Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg, the generic version of Nitrostat® Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg, of Pfizer, Inc.
According to IMS Health sales data for the 12 month period ending July 2017, the Nitrostat® Sublingual Tablets, 0.3 mg, 0.4 mg, and 0.6 mg market1 achieved annual sales of approximately $112.7 million*.
Glenmark's current portfolio consists of 125 products authorized for distribution in the U.S. marketplace and 61 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.611.4 as compared to the previous close of Rs. 615.45. The total number of shares traded during the day was 79844 in over 1724 trades.
The stock hit an intraday high of Rs. 622 and intraday low of 610.5. The net turnover during the day was Rs. 48987060.
All brand names and trademarks are the property of their respective owners.
1Market includes brand and all available therapeutic equivalents
*IMS Health National Sales Perspectives: Retail & Non-Retail, July 2017